NCT00578305View on ClinicalTrials.gov

A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate

PHASE3CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

May 31, 2013

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Rituximab

Rituximab was supplied as a sterile liquid for iv administration.

DRUG

Placebo

Placebo was supplied as a sterile liquid in single-use vials for iv administration.

DRUG

Methylprednisolone

DRUG

Methotrexate

DRUG

Folic acid or folate

Trial Locations (60)

1002

Riga

1038

Riga

2100

Copenhagen

2650

Hvidovre

3010

Bern

3400

Hillerød

10117

Berlin

11000

Belgrade

11312

Tallinn

13419

Tallinn

18250

Niška Banja

28046

Madrid

29010

Málaga

30625

Hanover

31059

Toulouse

34098

Istanbul

34295

Montpellier

35100

Izmir

41009

Seville

45032

Orléans

46017

Valencia

54636

Thessaloniki

83043

Bad Aibling

91054

Erlangen

115522

Moscow

195067

Saint Petersburg

394066

Voronezh

400006

Cluj-Napoca

420097

Kazan'

74110010

Goiânia

C1280AEB

Buenos Aires

80030-110

Curtiba

90610-000

Porto Alegre

04023-900

São Paulo

R3E0W3

Winnipeg

A1A 5E8

St. John's

K1H 1A2

Ottawa

K2G 6E2

Ottawa

M4N 3M5

Toronto

H1T 2M4

Montreal

H2L 1S6

Montreal

H3Z 2Z3

Montreal

G1V 3M7

Québec

S7M 0Z9

Saskatoon

625 00

Brno

370 01

České Budějovice

128 50

Prague

06202

Nice

01307

Dresden

06120

Halle

115 27

Athens

265 04

Pátrai

LT-08661

Vilnius

1105 AZ

Amsterdam

0370

Oslo

020475

Bucharest

08003

Barcelona

08907

Barcelona

01330

Adana

06018

Ankara

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00578305 - A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate | Biotech Hunter | Biotech Hunter